bioRxiv · 10.1101/2024.07.05.602135
'Target-and-release' nanoparticles for effective immunotherapy of metastatic ovarian cancer
Abstract
Immunotherapies such as checkpoint inhibitors (CPI) are effective in treating several advanced cancers, but these treatments have had limited success in metastatic ovarian cancer (OC). Here, we engineered liposomal nanoparticles (NPs) carrying a layer-by-layer (LbL) polymer coating that promotes their binding to the surface of OC cells. Covalent anchoring of the potent immunostimulatory cytokine interleukin-12 (IL-12) to phospholipid headgroups of the liposome core enabled the LbL particles to concentrate IL-12 in disseminated OC tumors following intraperitoneal administration. Shedding of the LbL coating and serum protein-mediated extraction of IL-12-conjugated lipids from the liposomal core over time enabled IL-12 to disseminate in the tumor bed following rapid NP localization in tumor nodules. Optimized IL-12 LbL-NPs promoted robust T cell accumulation in ascites and tumors in mouse models, extending survival compared to free IL-12 and remarkedly sensitizing tumors to CPI, leading to curative treatments and immune memory.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Pires, I. S., Covarrubias, G., Gomerdinger, V. F., Backlund, C. M., Shanker, A., Gordon, E., Wu, S., Pickering, A. J., Melo, M. B., Suh, H., Irvine, D. J., Hammond, P. T.. 2024-07-07. 'Target-and-release' nanoparticles for effective immunotherapy of metastatic ovarian cancer. https://doi.org/10.1101/2024.07.05.602135
Cite the original work for its findings. Save a collection to share your selection of sources.